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Abstract
Lactate has long been considered a “waste” by-product of cell metabolism, and it accumu-
lates at sites of inflammation. Recent findings have identified lactate as an active metabolite
in cell signalling, although its effects on immune cells during inflammation are largely unex-
plored. Here we ask whether lactate is responsible for T cells remaining entrapped in inflam-
matory sites, where they perpetuate the chronic inflammatory process. We show that
lactate accumulates in the synovia of rheumatoid arthritis patients. Extracellular sodium lac-
tate and lactic acid inhibit the motility of CD4+ and CD8+ T cells, respectively. This selective
control of T cell motility is mediated via subtype-specific transporters (Slc5a12 and
Slc16a1) that we find selectively expressed by CD4+ and CD8+ subsets, respectively. We
further show both in vitro and in vivo that the sodium lactate-mediated inhibition of CD4+ T
cell motility is due to an interference with glycolysis activated upon engagement of the
chemokine receptor CXCR3 with the chemokine CXCL10. In contrast, we find the lactic
acid effect on CD8+ T cell motility to be independent of glycolysis control. In CD4+ T helper
cells, sodium lactate also induces a switch towards the Th17 subset that produces large
amounts of the proinflammatory cytokine IL-17, whereas in CD8+ T cells, lactic acid causes
the loss of their cytolytic function. We further show that the expression of lactate transport-
ers correlates with the clinical T cell score in the synovia of rheumatoid arthritis patients.
Finally, pharmacological or antibody-mediated blockade of subtype-specific lactate trans-
porters on T cells results in their release from the inflammatory site in an in vivo model of
peritonitis. By establishing a novel role of lactate in control of proinflammatory T cell motility
and effector functions, our findings provide a potential molecular mechanism for T cell
entrapment and functional changes in inflammatory sites that drive chronic inflammation
and offer targeted therapeutic interventions for the treatment of chronic inflammatory
disorders.
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Author Summary
Acidity is a feature of inflammatory sites such as arthritic synovia, atherosclerotic plaques,
and tumor microenvironments and results in part from the accumulation of lactate as a
product of glycolysis under hypoxic conditions. Recently it has emerged that lactate may
be more than just a bystander and might act to modulate the immune-inflammatory
response. Here we report just such activity: lactate inhibits T cell motility by interfering
with glycolysis that is required for T cells to migrate, it causes T cells to produce higher
amounts of the proinflammatory cytokine IL-17, and it triggers loss of cytolytic activity.
These phenomena are hallmark features of T cells in chronic inflammatory infiltrates. The
functional changes depend on the expression of specific lactate transporters by different
subsets of T cells, namely the sodium lactate transporter Slc5a12 in CD4+ T cells and the
lactic acid transporter Slc16a1 in CD8+ T cells. We propose that T cells entering inflamma-
tory sites sense high concentrations of lactate via their specific transporters. Loss of motil-
ity leads to their entrapment at the site, where through their increased production of
inflammatory cytokines yet decreased cytolytic capacity, they add detrimentally to chronic
inflammation. Targeting lactate transporters and/or metabolic pathways on T cells could
deliver novel, invaluable therapeutics for the treatment of widespread chronic inflamma-
tory disorders.
Introduction
Recent studies have shed light on the interconnection between metabolism and immunity in
multicellular organisms and their functional coordination for an effective establishment and
resolution of immune responses. Imbalance of this delicate signaling network might lead to
nonresolving inflammation and consequently to the development of chronic inflammatory
disease (CID) [1].
T cells play a major role in the inflammatory process via both their cytolytic activities and
the production of pro- and anti-inflammatory cytokines, which regulate immune responses.
Upon antigen recognition by the T cell receptor (TCR), downstream signaling events in naïve
T cells lead to activation, proliferation and differentiation into effector T cells. To maintain
adequate supply of macromolecules (e.g., amino acids, nucleotides, and fatty acids) during
growth, T cells undergo a metabolic switch from oxidative phosphorylation to aerobic glycoly-
sis that is driven by signaling events generated by the TCR and the costimulatory molecule
CD28 [2,3]. The metabolic machinery is also likely to directly affect T cell migratory events, as
T lymphocytes continuously recirculate between different microenvironments (e.g., blood,
lymphoid tissues, and peripheral tissues), which might in turn modulate T cell metabolism. In
these “milieus”, they are exposed to different nutrient availability and oxygen (O2) tension and
must adapt their metabolic pathways to effectively mediate immune responses. The direct
effect of metabolism on the trafficking ability of T cells, however, is yet to be investigated [4].
A metabolic switch to aerobic glycolysis comprises the up-regulation of glycolytic enzymes
and glucose transporters to the membrane, leading to an increase in glycolytic flux and the con-
comitant production of lactate [4]. This carbon molecule has long been considered a metabolic
“waste” by-product of highly proliferating cells. Recently, this view has been challenged by the
observation that lactate can act as a signaling molecule and provide a “danger” signal [5,6].
Findings that endothelial cells and human cytotoxic T lymphocyte (CTL) can take up extracel-
lular lactate [7,8], that lactate inhibits phosphofructokinase (Pfk) [9], and that exposure to lac-
tate leads to a dramatic change in gene expression in L6 muscle cells [10] have shed light on the
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complexity and scope of lactate as an active metabolite driving signaling pathways that modu-
late cell functions.
Proinflammatory chemokines such as chemokine (C-X-C motif) ligand (CXCL)10 are pro-
duced in response to inflammatory stimuli and attract effector T cells to the site of inflamma-
tion to fulfill their effector functions [11]. Inflammatory sites, however, are “harsh”
microenvironments enriched with factors released by cellular components of the inflammatory
infiltrates and the injured tissue itself that might affect the behavior of effector T cells and influ-
ence the outcome of the immune response [12]. A key feature of the inflammatory microenvi-
ronment is the accumulation of lactate, a by-product of the glycolytic pathway. Depending on
the pH, lactate exists as the protonated acidic form (lactic acid) in a low pH environment or as
sodium salt (sodium lactate) at basic pH [13]. In physiological conditions (pH 7.2), most of the
lactate is deprotonated and is present in the negatively charged, biologically active form as lac-
tate anion [13].
In this study, we have investigated, both in vitro and in vivo, the role of lactate in the regula-
tion of metabolic and inflammatory circuits in control of T cell migration and functions and its
relevance to the physiopathology of CID.
Results
Lactate Inhibits Activated T Cell Motility
To assess whether T cell motility is affected by lactate, we performed assays whereby chemo-
taxis of T cells activated for 5 d with anti-CD3 and anti-CD28 antibodies, and interleukin (IL)-
2 was induced by the proinflammatory chemokine CXCL10 in the presence of 10 mM lactic
acid or sodium lactate, a concentration of lactate we measured in the synovial fluid of rheuma-
toid arthritis (RA) patients (Fig 1A) and found in a number of inflammatory sites [14,15].
CD4+ T cell chemotaxis was inhibited by sodium lactate whereas that of CD8+ T cells was
inhibited by lactic-acid but not vice versa (Fig 1B and 1C).
As T cell migration is activated by several chemokines, leading to different responses [11],
we also tested the effect of lactate on chemokine (C-C motif) ligand (CCL)5-induced chemo-
taxis. CCL5-induced motility of CD4+ T cells was decreased in sodium lactate–rich but not lac-
tic acid–rich environments (S1A Fig), suggesting a broader action of lactate in
chemokine-induced signaling and downstream effects than we had anticipated in our experi-
ments shown in Fig 1B and 1C. Motility of CD4+ T cells upon sodium lactate treatment
decreased with increasing concentration of sodium lactate with a half maximal effective con-
centration (EC50) of about 10 mM sodium lactate (Fig 1D). These concentrations of sodium
lactate and lactic acid did not affect cellular viability (S1B Fig).
As acidification “per se” could affect cellular motility [16], we performed additional chemo-
taxis assays to discriminate the effects of lactic acid on the motility of CD8+ T cells from the
effects of pH reduction in the culture media due to the addition of 10 mM lactic acid. Lactate is
present in solution either as the acid in its undissociated form (i.e., lactic acid) at low pH or as
the ion salt (i.e., sodium lactate) at higher pH. We found that progressive acidification of
medium containing sodium lactate (10 mM)—which increases the availability of lactic acid—
reduced the motility of CD8+ T cells (Fig 1E). Importantly, neither the presence in the culture
media of sodium lactate (10 mM) alone nor acidifying the culture media to pH 4.5 with HCl
alone had any effects on the motility of CD8+ T cells (Fig 1E). In line with recently reported
findings in macrophages [17], our data show that inhibition of CD8+ T cell motility by lactic
acid cannot be simply ascribed to its effect on the acidification of the culture media; rather
simultaneous availability of lactate and H+ is necessary to regulate the motility of CD8+ T cells.
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Fig 1. Lactate inhibits T cell motility. (A) Lactate measurements in the synovial fluid of osteoarthritis (OA) or RA patients. (B–C) In vitro chemotaxis of
activated CD4+ (B) and CD8+ (C) T cells towards CXCL10 (300 ng/ml) in the presence of lactic acid (10mM) or sodium lactate (10 mM) shown as kinetic (left
panel) and 4 h time point (right panel). (D) In vitro chemotaxis of activated CD4+ T cells towards CXCL10 (300 ng/ml) in the presence of increasing
concentration of sodium lactate shown as kinetic (left panel) and 4 h time point (right panel). (E) In vitro chemotaxis (4 h time point) of activated CD8+ T cells
towards CXCL10 (300 ng/ml) in the presence of sodium lactate (10 mM) or HCl (pH 4.5) alone, or sodium lactate in combination with increasing
concentrations of HCl to obtain progressively reduced pH as indicated in figure. (A) OA, n = 4 and RA n = 8. (B right panel) n = 4. (C–D right panel, E) n = 3.
(B–D left panel) Data is representative of three independent experiments; the underlying numerical data and statistical analysis for each independent
experiment can be found in the supporting file, S1 Data, Fig 1B–1D. (A–E) Underlying numerical data and statistical analysis can be found in the supporting
file, S1 Data, Fig 1A–1E. Values denote mean ± standard deviation (SD). * p <0.05; ** p <0.01; *** p <0.001.
doi:10.1371/journal.pbio.1002202.g001
Lactate Controls T Cell Immunity
PLOS Biology | DOI:10.1371/journal.pbio.1002202 July 16, 2015 4 / 24
This effect did not apply to CD4+ T cells since their migration was not affected in lactic acid–
rich medium (Fig 1B).
The Effects of Lactate Action on Different T Cell Subsets Are Mediated
by Distinct Transporters
We next investigated the molecular basis of the differential and mutually exclusive respon-
siveness of CD4+ and CD8+ T cells to sodium lactate or lactic acid, respectively. Fischer et al.
described the expression by human cytotoxic lymphocytes of Slc16a1 (also known as mono-
carboxyl transporter [Mct]1), a lactate-H+ symporter which facilitates lactic acid uptake [7].
Slc5a12 is a sodium-coupled lactate transporter [18]. We found that murine CD8+ and
CD4+ T cells selectively express Slc16a1 (NM_009196.4) and Slc5a12 (NM_001003915.2),
respectively (Fig 2A), suggesting a specific functional role of each transporter on each T cell
subset.
We subsequently sought to confirm that the differently expressed lactate transporters were
functional in T cell chemotaxis inhibition. Blockade of Slc16a1 on CD8+ T cells with the selec-
tive inhibitors phloretin, α-cyano-4-hydroxycinnamate (CHC) [19], and AR-C155858 [20], or
with a specific antibody restored chemotaxis of CD8+ T cells exposed to lactic acid (Fig 2B and
2C). Conversely, chemotaxis of CD4+ T cells in sodium lactate–rich media was recovered fol-
lowing selective inhibition of Slc5a12 on CD4+ T cells with lentiviral-delivered, specific short
hairpin RNAs (shRNAs) or a specific antibody (Fig 2D and S2A Fig). As expected, the anti-
Slc5a12 antibody or shRNAs targeting Slc5a12 did not affect CD8+ T cell migration (S2B Fig),
nor did the Slc16a1 inhibitors phloretin, CHC and AR-C155858 or the anti-Slc16a1 antibody
affect migration of CD4+ T cells (S2C Fig).
Sodium Lactate Limits Basal and Chemokine-Induced Aerobic
Glycolysis in CD4+ T Cells
The lactate transporters specificity (Fig 2A) and the T cell insensitivity to lactate upon trans-
porter inhibition (Fig 2B–2D, S2B and S2C Fig) suggest that the effects of lactate are mediated
by intracellular signaling, possibly interfering with the cell metabolic machinery, and specifi-
cally with the glycolytic pathway [9], engaged downstream of chemokine receptor triggering.
We started by investigating the effect of CXCL10 treatment in the presence or absence of
lactate on the induction of glycolysis in CD4+ and CD8+ T cells activated for 3 d with anti-
-CD3 and anti-CD28 antibodies and IL-2. Glycolytic enzymes are expressed in naive T cells
and their expression is markedly increased upon T cell activation [21]; nevertheless, we found
that CXCR3 engagement with CXCL10 was able to cause a further significant up-regulation of
two rate-limiting enzymes in the glycolytic pathway, Hk1 (NM_00114100.1) and pyruvate
kinase (Pk)M1/2 (NM_011099.3) (Fig 3A). Specifically, data quantification across indepen-
dent experiments revealed significant up-regulation of Hk1 at 2 h and PkM1/2 at 4 h post-
CXCL10 treatment, as compared to the levels expressed by activated CD4+ T cells left
untreated (Fig 3A right). Although Hk1 appears to be up-regulated also at 4 h post CXCL10
treatment as compared to the untreated control in the western blot shown in Fig 3A left, sta-
tistical analysis across independent experiments showed a slight down-regulation of Hk1 at
this point as compared to the untreated control (Fig 3A right). Similarly, Hk1 and PkM2
mRNA levels were up-regulated after 6 h of treatment with CXCL10 (Fig 3B). These data sug-
gest the existence of multiple levels of regulation of the glycolytic pathway downstream of
CXCR3 triggering, being both post-translational and transcriptional. In addition, activated
CD4+ T cell exposure to CXCL10 led to increased gene expression of glucose transporters (Fig
3B) [3]. Remarkably, data quantification across independent experiments also revealed that
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activated CD4+ T cells treated with CXCL10 in the presence of sodium lactate had signifi-
cantly reduced levels of Hk1 as compared to cells treated with CXCL10 alone (both at 2 and 4
h) or left untreated (only at 4 h; although a reduction appears also at 2 h in the western blot
shown in Fig 3A left as compared to the untreated control, this down-regulation did not reach
statistical significance across independent experiments [Fig 3A right]). In contrast, CD8+ T
cells did not undergo major changes in the expression of glycolytic genes and proteins upon
exposure to CXCL10 (S3A and S3B Fig).
Since glycolysis is selectively activated in CD4+ T cells upon CXCR3 triggering, we then
tested the effects of sodium lactate on the glycolytic energy metabolism of CD4+ T cells under
basal conditions by measuring the extracellular acidification rate (ECAR) in the cell culture
media of CD4+ T cells in real time via the use of the Seahorse analyzer. We found that sodium
lactate decreased the ECAR of CD4+ T cells from an average of 14 mpH/min in the untreated
control to a level of less than 5 mpH/min (Fig 3C), indicating a decrease in glycolytic flux. In
Fig 2. Sodium lactate and lactic acid act on CD4+ and CD8+ T cell subsets, respectively, through specific cell membrane transporters. (A) Total
protein levels of the transporters Slc16a1 and Slc5a12 as assessed by western blot in activated CD4+ and CD8+ T cell subsets. (B–D) In vitro chemotaxis (4
h time point) of activated CD8+ T cells towards CXCL10 (300 ng/ml) in the presence of lactic acid (10 mM) alone, or in combination with α-cyano-
4-hydroxycinnamate (CHC) (425 μM), phloretin (25 μM), or anti-Slc16a1 antibody (2.5 μg/ml) (B), or increasing concentrations of AR-C155858 as indicated in
the figure (C), and activated CD4+ T cells towards CXCL10 (300 ng/ml) in the presence of sodium lactate (10 mM) alone, or in combination with an
anti-Slc5a12 antibody (2.5 μg/ml) or two specific short hairpin RNAs (shRNAs) (D). An isotype control antibody has been included to control for antibody
specificity (B, D), and a nonspecific shRNA has been included to control for gene knockdown specificity (D). (B–D) n = 3. Underlying numerical data and
statistical analysis can be found in the supporting file, S1 Data, Fig 2B–2D. Values denote mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.
doi:10.1371/journal.pbio.1002202.g002
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Fig 3. Basal and chemokine-induced aerobic glycolysis is required for CD4+ T cell migration. (A) Western blots with antibodies against Hk1, aldolase
A, PkM1/2, enolase 1, and β-actin in activated CD4+ T cells treated with CXCL10 (1,000 ng/ml) alone or in combination with sodium lactate (10 mM), or left
untreated. Densitometric quantification of western blots denotes mean ± SD, n = 3 (with biological replicates run in duplicate). *p < 0.05; ***p < 0.001. (B)
Relative mRNA expression levels of Hk1, PkM2, and glucose transporters (Glut1,Glut2,Glut3,Glut4) in activated CD4+ T cells 6 h post-treatment with
CXCL10 (1,000 ng/ml) as assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR). mRNA levels in naive CD4+ T cells were set
to 1. (C) Extracellular acidification rate (ECAR) trace of glycolytic activity expressed as mpH/min in activated CD4+ T cells treated with sodium lactate (10
mM) or phosphate buffered saline (PBS). Vertical lines represent addition times of sodium lactate or PBS, respectively. (D) Measurements of glucose uptake
and flux in activated CD4+ T cells pretreated with 2-deoxyglucose (2-DG) (1 mM), sodium-lactate (10 mM) or lactic acid (10 mM) and then incubated with the
fluorescent probes 6-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (6-NBDG) or 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-
2-Deoxyglucose (2-NBDG). (E) ECAR trace of glycolytic activity in activated CD4+ T cells treated with CXCL10 (1,000 ng/ml) and sodium lactate (10 mM).
Vertical lines represent the addition times of CXCL10, sodium lactate and PBS. (F) In vitro chemotaxis (4 h time point) towards CXCL10 (300 ng/ml) of
Lactate Controls T Cell Immunity
PLOS Biology | DOI:10.1371/journal.pbio.1002202 July 16, 2015 7 / 24
support of these data, we treated CD4+ or CD8+ T cells with the fluorescent analogues of glu-
cose, 6-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (6-NBDG), and 2-(N-
(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG), in the presence or
absence of sodium lactate or lactic acid [22]. We found lower 6-NBDG-fluorescence and higher
2-NBDG-fluorescence in sodium lactate–treated CD4+ T cells as compared to lactic acid–
treated or untreated CD4+ T cells suggesting that sodium lactate but not lactic acid selectively
blocks glucose uptake and glycolytic flux in CD4+ T cells; the opposite was observed in CD8+ T
cells (Fig 3D and S3C Fig). As expected, the inhibitor of glycolysis 2-deoxyglucose (2-DG)
showed similar effects on 2-NBDG and 6-NBDG fluorescence in both T cell subsets (Fig 3D
and S3C Fig), further indicating the specificity of the effects of sodium lactate and lactic acid in
CD4+ and CD8+ T cells, respectively.
We next investigated whether sodium lactate was able to diminish glycolysis also upon
CXCR3 engagement by CXCL10. Exposing CD4+ T cells to CXCL10 raised the ECAR value for
several time points, indicating that the glycolytic flux is increased in these conditions (Fig 3E)
[23]. Adding sodium lactate to the CXCL10-stimulated cells shut down glycolysis, as reflected
by a drastic fall in ECAR (Fig 3E).
Basal and Chemokine-Induced Aerobic Glycolysis Is Required for CD4+
T Cell Migration Both In Vitro and In Vivo
The down-regulation of glycolysis and the inhibitory effect on migration upon sodium lactate
exposure—lactate being a direct and indirect inhibitor of glycolysis [9]—suggest that glycolysis
is required for CD4+ T cell migration. To test this hypothesis, we treated activated CD4+ T cells
with inhibitors or activators of glycolysis and assessed their chemotactic responses to CXCL10.
Direct or indirect inhibition of glycolysis with the glucose analogue, 2-DG, or mTOR inhibitor,
rapamycin (S3D Fig), caused a decrease in chemotaxis in vitro and in a well-established in vivo
model of T cell recruitment to the peritoneum (Fig 3F and 3G, and S3E Fig) [24]. Conversely,
activation of glycolysis via the use of the electron transfer chain Complex I inhibitor, metfor-
min (S3D Fig) [25–28], increased chemotaxis towards CXCL10 both in vitro and in vivo (Fig
3F and 3G and S3E Fig). Accounting for the specificity of our glycolytic measurements, eto-
moxir, an inhibitor of fatty acid oxidation, had only minor effects on glycolysis (S3D Fig).
Metabolic drugs interfering with glycolysis had similar effects on T cell motility in spontane-
ous transendothelial migration assays (i.e., independent of any proinflammatory chemokine
stimulus), implying the role of this pathway in steady-state control of T cell migration (Fig
3H). Importantly, exposure to the various metabolic drugs at the concentrations used did not
affect the T cell surface molecule phenotype (S4 and S5 Figs).
The importance of aerobic glycolysis in activation and function of T cells has been shown
previously [2,29,30], yet its potential impact on T cell migration is still unexplored; thus we
assessed the impact of glycolysis on migration of naïve T cells, which mainly rely upon oxida-
tive metabolism for their homeostasis [2]. Similar to what we had observed in activated T cells,
inhibition of glycolysis via 2-DG and rapamycin resulted in a decrease in naïve T lymphocyte
motility (S3F Fig), suggesting a general control of T cell migration via the glycolytic pathway.
activated CD4+ T cells pretreated with Rapamycin (200 nM), 2-DG (1 mM) or Metformin (2 mM). (G) Relative enrichment of IV-injected activated CD4+ T cells
pretreated with Rapamycin (200 nM), 2-DG (1 mM) or Metformin (2 mM) and subsequently labelled with 7-Hydroxy-9H-(1,3-Dichloro-9,9-Dimethylacridin-
2-One (DDAO) cell fluorescent dye in the peritoneal lavage of syngeneic recipient C57BL/6 mice i.p. injected with CXCL10 (120 ng/mouse). (H) Spontaneous
transendothelial migration (6 h time point) of activated CD4+ T cells in the presence of rapamycin (200nM), 2-DG (1 mM) or metformin (2 mM). (B–C, E) Data
is representative of three independent experiments; the underlying numerical data and statistical analysis for each independent experiment can be found in
the supporting file, S1 Data, Fig 3B–3C, 3E. (D, F, H) n = 3. (G) n = 4. (A–H) Underlying numerical data and statistical analysis can be found in the supporting
file, S1 Data, Fig 3A–3H. Values denote mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.
doi:10.1371/journal.pbio.1002202.g003
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In contrast to activated T cells, however, exposure to metformin reduced naïve T cell migration
(S3F Fig), indicating the existence of different metabolic checkpoints between naïve and acti-
vated T cells [31].
Overall, metabolic drugs did not affect T cell survival at the concentrations and in the exper-
imental conditions we used (S5 Fig).
Lactate Modulates Effector T Cell Functions
To investigate whether sodium lactate could affect CD4+ T cell effector functions, we induced
polarization of CD4+ T cells towards Th1, Th2, and Th17 subsets in the appropriate cytokine
“milieus” [32,33]. The expected patterns of cytokine expression by differentiated Th subsets were
confirmed at the mRNA level (S6 Fig). We then tested the effect of the presence of sodium lactate
on the release of cytokines by the different Th subsets in the same polarizing conditions. Gene
expression analysis showed that treatment with sodium lactate caused a significant up-regulation
of Il-17 (NM_010552.3) in all the Th subsets (Fig 4A). Supporting these data, gene expression of
Rorc (NM_011281.2), the signature transcription factor of Th17 cells, was also significantly ele-
vated in all the Th subsets upon T cell exposure to sodium lactate (Fig 4A). Gene expression of
Th1 and Th2 signature cytokines instead was unmodified upon treatment with sodium lactate
(Fig 4A). Intracellular staining experiments confirmed the increased expression of IL-17 protein
in CD4+ T cells exposed to sodium lactate as compared to cells left untreated (Fig 4B). Remark-
ably, preincubation with the antibody anti-Slc5a12 blocked the up-regulation of Il-17 and Rorc
genes induced by sodium-lactate (Fig 4C).
CTL differentiating from the CD8+ subset express and release cytolytic granules consisting
of perforin/granzyme complexes, which promote the killing of target cells [34]. To test whether
these functions were affected by lactate, we performed cytotoxicity assays with allogeneic endo-
thelial cells. Similarly to the results obtained in migration assays (Fig 1C), lactic acid but not
sodium lactate inhibited the cytolytic activity of CTL (Fig 4D).
Inhibition of Lactate Transporters Promotes the Release of T Cells from
the Inflamed Tissue
We have shown that in humans the synovial fluid of RA contains elevated levels of lactate com-
pared with noninflammatory types of arthritis (e.g., osteoarthritis [OA], Fig 1A). The rheuma-
toid synovial environment is paradigmatic of all the lactate-induced changes in T cells,
including entrapment, IL-17 secretion and loss of antigen responsiveness [35]. We therefore
investigated the expression and cellular localization of Slc5a12 and Slc16a1 within the synovial
tissue of 16 patients suffering from RA (S1 Table, demographical data). We first stratified RA
patients for the amount of CD3+ infiltrating T cells using a semiquantitative score (Fig 5A) as
we previously described [35]. Next, we performed gene expression analysis and found that
Slc5a12mRNA expression significantly increased in correlation with the T cell score of the
samples tested (Fig 5B). Albeit not significant, a trend towards increased Slc16a1 expression
could also be observed in CD8+ T cells (Fig 5B). In order to confirm our in vitro data that
Slc5a12 is expressed on CD4+ but not CD8+ T cells (Fig 2A), we performed double immunoflu-
orescence for Slc5a12 and either CD4 or CD8. As shown in Fig 5C, within the RA synovial tis-
sue Slc5a12 is abundantly and selectively expressed by CD4+ but not CD8+ T cells. Enhanced
expression of the Slc5a12 transporter by CD4+ T cells in the RA synovia opens the possibility
that this transporter might be mediating the migratory and functional changes that we have
previously described and that correlate with key features of T cell infiltrates in RA. In support
to this, we found that CD4+ and CD8+ T cells isolated from the peripheral blood of human
healthy donors responded in vitro to sodium lactate and lactic acid similarly to their murine
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Fig 4. Lactate modulates effector T cell functions. (A) Relative mRNA expression levels of the cytokines interferon-gamma (Ifn-γ), Tnf-β, Il-4, Il-5, Il-13,
and Il-17 and of the transcription factor Rorc as assessed by qRT-PCR in CD4+ subsets Th0, Th1, Th2, and Th17 treated with sodium lactate (10 mM) or left
untreated. mRNA levels of each cytokine expressed by untreated Th0 cells were set to 1. (B) Intracellular staining of IL-17A and IFN-γ in activated CD4+ T
cells treated with sodium lactate (10 mM) or left untreated. (C) Relative mRNA expression levels of Il-17 and Rorc in activated CD4+ T cells treated with
sodium lactate alone or in combination with an anti-Slc5a12 antibody. mRNA levels of untreated T cells were set to 1. (D) Cell survival of allogeneic
endothelial cells in the presence of CD8+ cytotoxic T cells and lactic acid (10 mM) or sodium lactate (10 mM) shown as kinetic (left panel) and 6 h time point
(right panel). (A, C, D left panel) Data is representative of three independent experiments; the underlying numerical data and statistical analysis for each
independent experiment can be found in the supporting file, S1 Data, Fig 4A, 4C, and 4D. (B, D right panel) n = 3. (A–D) Underlying numerical data and
statistical analysis can be found in the supporting file, S1 Data, Fig 4A–4D. Values denote mean ± SD. *p < 0.05; **p < 0.01.
doi:10.1371/journal.pbio.1002202.g004
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Fig 5. High Slc5a12 expression in RA in humans. (A) Representative images of RA synovial tissues stained for CD3 displaying progressively higher
degree of T cell infiltration as quantified using a semiquantitative score from T0 (absence of infiltrating T-cells) to T3 (large number of infiltrating T cells
organizing in ectopic follicles) as shown in [35]. (B) Relative mRNA expression levels of Slc16a1 and Slc5a12 in the synovial fluid isolated from the joints of
RA patients. Samples are grouped based on their T cell score as described in A. Values denote mean ± SD, (T0) n = 6 and (T2–3) n = 7. *p < 0.05. (C)
Double immunofluorescence staining for Slc5a12 and CD4 or CD8 in the synovial tissue of RA patients. Slc5a12 (green) is highly expressed within the RA
synovia in the presence of a high degree of CD4+ (red) T cell infiltration. Merging (yellow) of the green and red channels demonstrates that Slc5a12 is
selectively expressed by CD4+ but not CD8+ infiltrating T cells. Quantification of the % double positive cells is provided upon counting positive cells (single
and double positive for each marker) in at least 6 images per condition. Columns represent % of double positive CD4+ Slc5a12+ population within the CD4+ or
Slc5a12+ cells and % of double positive CD8+ Slc5a12+ population within the CD8+ or Slc5a12+ cells. Scale bars: 50 μm. (D) In vitro chemotaxis (4 h time
point) of activated human CD4+ and CD8+ T cells towards CXCL10 (300 ng/ml) in the presence of lactic acid (10 mM) or sodium lactate (10 mM). (E)
Intracellular staining of IL-17A in activated human CD4+ T cells treated with sodium lactate (10 mM) or left untreated. (D) n = 3. (E) n = 4. (B–E) Underlying
numerical data and statistical analysis can be found in the supporting file, S1 Data, Fig 5B–5E. Values denote mean ± SD. *p < 0.05.
doi:10.1371/journal.pbio.1002202.g005
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counterparts in terms of migration (i.e., activated human CD4+ and CD8+ T cells; Fig 5D) and
expression of IL-17 protein (i.e., activated human CD4+ T cells upon exposure to sodium lac-
tate as compared to cells left untreated; Fig 5E).
Prompted by these results, we sought to assess whether lactate promotes the retention of T
cells into inflammatory sites in vivo and whether inhibitors of the lactate transporters favor the
release of T cells from the inflamed site. We used a well-established mouse model of zymosan-
induced peritonitis, in which T cells are recruited to the inflamed site 5 d after zymosan injec-
tion [36]. C57BL/6 mice were injected in the peritoneal cavity with zymosan (1 mg/mouse) on
day 0 or left untreated. On day 5, phloretin, an anti-Slc5a12 antibody or an isotype control
antibody were injected into the peritoneal cavity. 24 h later, mice were killed and the peritoneal
lavage was harvested. Lactate levels and CD4+ and CD8+ T cells were increased significantly in
the peritoneum of recipient animals (Fig 6A and 6B). Intraperitoneal injection of anti-Slc5a12
antibody caused a significant reduction of CD4+ T cells in the peritoneum in comparison to an
isotype control antibody, while having no effect on CD8+ T cells (Fig 6B, S7A, and S7B Fig). In
contrast, phloretin promoted a significant decrease of CD8+ T cells in the peritoneum but did
not show any effect on CD4+ T cells (Fig 6B, S7A, and S7B Fig).
To establish that the decrease in T cell localization to the peritoneal cavity was at least in
part due to their increased egression from this site, we performed adoptive transfer experi-
ments whereby carboxyfluorescein succinimidyl ester (CFSE)-labelled CD4+ T cells were coin-
jected with anti-Slc5a12 antibody, phloretin, or an isotype control antibody in the peritoneal
cavity of mice which had received zymosan (1 mg/mouse) 5 d before, to create an environment
rich of lactate (Fig 6A). 24 h after the intraperitoneal injection of CFSE-labelled CD4+ T cells,
mice were killed, and peritoneal lavage and spleen were harvested. Injection with anti-Slc5a12
antibody but not phloretin or the isotype control antibody in the peritoneal cavity caused a
reduction of adoptively transferred T cells in the peritoneum and their accumulation in the
spleen (Fig 6C and S7C Fig).
Discussion
CIDs are a major public health concern in the western world. The nonresolving nature of
inflammation in CID, associated with excessive and inappropriate activation of the immune
system, is pivotal to the disease process and represents a treasure trove for drug discovery via
the identification of novel processes and molecules that could be targeted for the design of new
therapeutics.
In this study, we have identified a key role for the glycolytic pathway and its metabolite, lac-
tate, in the regulation of T cell migration and functions in inflammation. Lactate can be
imported into the cell through specific transporters and acts as a potent inhibitor of two of the
rate-limiting enzymes in the glycolytic pathway, Hk (catalyzing the first reaction) and Pfk (the
key enzyme in setting the pace of glycolysis, which catalyzes the third reaction), but does not
affect Pk (the third rate-limiting enzyme in glycolysis, which catalyzes the tenth and last reac-
tion) [9]. Consistently, our data show lactate-induced down-regulation of Hk1 but not PkM1/2
protein levels. Unlike Hk1 and PkM1/2, we did not find any significant regulation of Pfk upon
CXCL10 stimulus. Nevertheless, our data shows that lactate down-regulates Hk1, which is suf-
ficient to reduce the glycolytic flux and in turn causes reduced T cell migration. In recent years,
aerobic glycolysis has been associated with cell division in a number of physiological (e.g.,
immunity, stem cell compartment) [31,37,38] and pathological (e.g., cancers) processes
[39,40]. Very recently, however, a metabolic switch to aerobic glycolysis has been linked to
more specialized–independent of proliferation–cell functions, such as interferon-gamma (IFN-
γ) production in T cells [29] and vessel sprouting in endothelial cells [41]. In the latter study,
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glycolysis has been directly linked to cytoskeleton reorganization and migration of endothelial
cells during neoangiogenesis via the glycolytic activator 6-phosphofructo-2-kinase/fructose-
2,6-biphosphatase 3 (PFKFB3). Up to date, a direct link between T cell migration and intracel-
lular metabolic pathways had not been established [3,4]. Our study provides direct evidence
Fig 6. Inhibition of lactate transporters promotes the release of T-cells from the inflamed site in
zymosan-induced peritonitis. (A) Lactate levels in the peritoneum of zymosan-treated mice. (B) Number of
CD4+ and CD8+ T cells, respectively, in the peritoneal lavage of C57BL/6 mice injected i.p. with zymosan (1
mg/mouse) to induce peritonitis, and 5 d later, i.p. treated with phloretin (50 μM), an anti-Slc5a12 antibody
(5 μg/ml) or an isotype control antibody. (C) Number of carboxyfluorescein succinimidyl ester (CFSE)-labeled
activated CD4+ T cells in the peritoneal lavage (left panel) or spleen (right panel), respectively, of C57BL/6
mice injected i.p. with zymosan (1 mg/mouse), then i.p. treated with phloretin (50 μM), an anti-Slc5a12
specific antibody (5μg/ml) or an isotype control antibody. (A–C) n = 3 or more. Underlying numerical data and
statistical analysis can be found in the supporting file, S1 Data, Fig 6A–6C. Values denote mean ± SD. *p <
0.05; **p < 0.01; ***p < 0.001.
doi:10.1371/journal.pbio.1002202.g006
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that intracellular metabolism, specifically glycolysis, is required for chemokine-induced T cell
migration. Further studies will be required to identify specific factors and pathways to causally
link the induction of aerobic glycolysis that happens during T cell migration in response to the
chemokine stimulus to actin and cytoskeleton reorganization as well as its physiological
impact.
The effect of lactate on T cells is exerted via transporters, which are differentially
expressed by CD4+ and CD8+ T cells. This is a previously unknown feature that differentiates
these two subsets. As T cells are likely to be exposed to lactate as a consequence of the high
proliferation rates in the thymus, it is possible that the expression of either transporter is
determined and functional during development and might be regulated by other develop-
mental signals, such as TCR engagement. The physiological significance of distinct lactate
transporter expression by CD4+- and CD8+-activated T cells might dictate their functional
and migratory responses depending on the nature of the inflammatory exudate (i.e., more
lactic acid versus sodium lactate) and underlay the differential distribution of these T cell
subsets in the inflamed tissue, as it has been described in tumours and CIDs [42–44]. Clarify-
ing the molecular mechanisms and physiological significance of this differential expression
will require further investigations.
The effect of lactate on T cells recapitulates key features of T lymphocytes found in chronic
inflammatory infiltrates, including their entrapment and production of high levels of IL-17
and loss of cytolytic activity by CD4+ and CD8+ T cells, respectively (Fig 7A) [2,12]. We show
that sodium lactate induces all CD4+ Th subsets to increase their production of the proinflam-
matory cytokine IL-17, which is prevalent in the inflamed tissue and is known to drive forward
the chronic inflammatory process in many CIDs [2,12]. Previous reports have shown that HIF-
induced glycolysis is necessary to promote the differentiation of naïve CD4+ T cells toward the
Th17 subset [45]. We have analyzed memory T cells already committed to a specific subset,
similar to T cells in the inflammatory site. After in vitro incubation with sodium lactate, these
cells acquire a mixed phenotype whereby they continue to express their own signature cyto-
kines but at the same time increase the expression of Rorγt and IL-17. In this context, it has
recently been suggested that increased salt (sodium chloride, NaCl) concentrations found
locally under physiological conditions in vivo markedly boost the induction of murine and
human Th17 cells in autoimmune conditions [46]. Our results expand this observation to a
broader range of salts, including sodium lactate. In keeping with the in vitro data, we also show
that in the chronically inflamed synovial tissue of patients with RA, a disease associated with
high levels of IL-17+/CD4+ T cells in the joints [47], infiltrating CD4+, but not CD8+, T cells
almost invariably displayed high expression of Slc5a12. This suggests that the expression of
Slc5a12 on the CD4+ subset may be involved in the entrapment of CD4+ T cells within the
chronically inflamed “milieu” of the RA synovia (Fig 7A). In this context, we show that target-
ing the lactate transporters Slc16a1 and Slc5a12 re-establish T cell migration away from the
inflammatory site and block the production of high amounts of IL-17, with potential therapeu-
tic implications in the management of CIDs (Fig 7B). The mechanisms for lactate-mediated
induction of IL-17 production are at present unclear; further studies will be required to assess
whether such control occurs at metabolic level. These findings also suggest the idea that ele-
vated lactate concentrations within an inflamed site might sustain persistent inflammation by
reducing T lymphocyte cytolytic killing activity (Fig 7A) [33].
In summary, our observations suggest that lactate-induced signaling in the inflammatory
“milieu”may promote many of the pathogenic features and persistence of the T cell infil-
trates. Importantly, we show that pharmacologic targeting of lactate transporters in T cells
might provide a novel and viable approach to resolve chronic T cell–mediated inflammation
in CIDs.
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Fig 7. Schematic of the proposedmechanism of lactate effects on T cells in the inflammatory site. (A) The motility of CD4+ and CD8+ T cells is blocked
once they get exposed to elevated levels of lactate in the inflammatory site. Lactic acid also causes loss of cytolytic activity by CD8+ T cells, and sodium
lactate promotes the production of IL-17 by CD4+ T cells. (B) Pharmacologic targeting of lactate transporters re-establish T cell migration away from the
inflammatory site and block the production of high amounts of IL-17.
doi:10.1371/journal.pbio.1002202.g007
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Materials and Methods
Ethical Statement
Human blood was obtained from healthy donors according to ethics approval from Queen
Mary Ethics Research Committee (QMERC2014/61). RA synovial tissue was collected after
informed consent according to ethics approval from Barts and the London NHS Trust (LREC
07/Q0605/29). All in vivo experiments were conducted under the UK Home Office regulation
(PPL 70/7443).
Chemicals and Reagents
Chemicals and reagents were purchased from Sigma-Aldrich & Co (UK), unless otherwise
specified.
T Cell Isolation, In Vitro Activation and Subset Enrichment
Murine T cells were isolated from lymph nodes of C57BL/6 mice and activated for 3 to 5 d with
plate bound anti-CD3 (1 μg/ml) and anti-CD28 (5 μg/ml) antibodies (BioLegend), and IL-2
(10 ng/ml; PeproTech). Murine CD4+ and CD8+ T cell subsets were isolated with commercially
available isolation kits (negative selection; Easysep, Invitrogen) according to manufacturer’s
instructions either prior or post activation according to experimental settings. Human PBMCs
were isolated from blood using a single density centrifugation (Histopaque 1077, Sigma-
-Aldrich). CD4+ or CD8+ T cells were then isolated from the PBMCs (negative isolation) using
Dynabeads
1
magnetic separation (Invitrogen), according to manufacturer’s instructions.
Untouched human CD4+ and CD8+ T cells were stimulated for 5 d with 0.5 μg/ml of soluble
anti-CD3 (clone Hit3a) and 0.5 μg/ml of anti-CD28 (clone CD28.2) (Biolegend), together with
10 ng/ml IL-2 (Peprotech).
Chemotaxis Assays
Chemotaxis assays were performed in 5 μm transwell inlays (Corning). In some experiments, T
cells were pretreated overnight with a number of drugs purchased from Calbiochem: Rapamy-
cin (200 nM), 2-DG (1 mM), Metformin (2 mM). In most experiments, 1 h before the assay
cells were incubated with lactic acid (10 mM) or sodium lactate (10 mM), either alone or in
combination with Phloretin (25 μM, corresponding to its Ki [inhibitor constant] for Slc16a1
(MCT1); phloretin can also target MCT4 with a Ki of 41 μM, thereby excluding issues of speci-
ficity at the concentration we used [19]), CHC (425μM, corresponding to its Ki for Slc16a1;
CHC can also target MCT4 with a Ki of 991 μM, thereby excluding issues of specificity at the
concentration we used [19]), AR-C155858 (8, 23, or 92 nM [Tocris Bioscience], covering its
IC50 of around 20 nM for Slc16a1 [20]; AR-C155858 binds to MCT2 with similar affinity as to
Slc16a1, but MCT2 is not expressed in CD8+ T cells [7]), Slc5a12 specific antibody (2.5 μg/ml;
Abcam) or Slc16a1 specific antibody (2.5 μg/ml; Abcam). 3 x 105 lymphocytes suspended in
migration medium (RPMI 2% FCS) were seeded in the upper transwell chamber; chemokines
(PeproTech) were added to the lower chamber: CXCL10 (300 ng/ml), CCL5 (50 ng/ml),
CCL19/21 (200 ng/ml of each chemokine). Migrated T cells were counted with a hemocytome-
ter 2, 4, and 6 h after seeding, then percent of migrated cells were calculated. In some assays,
microvascular endothelial cells (isolated from the lungs of C57BL/6 mice) were seeded (3 x
104/well) on 3 μm transwell inlays. On the following day, T cells (3 x 105/well) suspended in
migration medium were added to the top chamber of the transwell and incubated at 37°C with
5% CO2 to allow migration through the endothelial monolayers. Migrated T cells were counted
with a hemocytometer 6 h after seeding, then percent of migrated cells was calculated.
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RNA Isolation and Reverse Transcription
RNA was isolated from 106 cells or 10 mg RA synovial tissue using commercially available kits
(Qiagen) or Trizol (Life) according to the manufacturer’s instructions and assessed for quality
and quantity using absorption measurements. Reverse transcription to cDNA was performed
according to the manufacturer’s instruction (Applied Biosystems).
qRT-PCR
Gene expression analysis was done using SYBR Green Supermix (Biorad) in CFX connect light
cycler (Biorad), according to the manufacturer’s instructions. Gene-relative expression was cal-
culated using the ΔΔct method [48] and normalized to a reference control (Rplp0). Primers for
qRT-PCR were designed with the assistance of online tools (Primer 3Plus) using at least one
exon junction binding site per primer pair where possible. A complete list of primers used is
available in the supporting information (S2 Table).
Western Blot
Protein lysates were prepared from activated T cells in RIPA buffer. Proteins were separated
with SDS-PAGE and transferred to a Nylon membrane (GE Healthcare). Membranes were
blocked for 2 h at room temperature in 5%Milk/TBS-T, incubated overnight at 4°C with pri-
mary antibodies (1:1,000) and subsequently with HRP-conjugated secondary antibody (Amer-
sham Bioscience) (1:5,000). Antibodies against Hk1, Pk M1/2, Aldolase A, Enolase 1, and β-
actin were purchased from Cell Signaling; antibodies against Slc16a1 and Slc5a12 were pur-
chased from Abcam. Density of bands of glycolytic enzymes was calculated relative to β-actin
via the use of Image J software.
Lentivirus Preparation
Bacterial glycerol stocks containing shRNA plasmid clones targeting Slc5a12 were purchased
from Sigma and grown in Luria Bertani broth. Plasmids were isolated using Plasmid Maxi kit
(Qiagen). HEK293T-cells were grown in 10 x 10 cm cell culture dishes to 70% confluence and
transfected with plasmids using the calcium phosphate method. The supernatant was harvested
48 and 72 h after transfection and 100-fold concentrated in an ultracentrifuge. Aliquots were
stored at −80°C.
Lentiviral Transduction and sh-RNA-Mediated Gene Silencing
Primary CD4+ T cells were isolated from C57BL/6 murine lymph nodes and activated with
plate bound anti-CD3 and anti-CD28, and IL-2 for 3 d. On day 3, medium was changed and
cells were incubated with 25 μl virus/106 cells in the presence of polybrene (8 μg/ml). Virus was
removed 24 h later; T cells were washed twice with PBS and incubated for 24 h in complete
RPMI culture media.
Measurement of Lactate, Glycolysis, Glucose Uptake/Flux and Cell
Death
Lactate concentration was measured in the synovial fluid or peritoneal lavage using the Lactate
assay Kit (Biovision), according to the manufacturer’s instructions. Glycolytic metabolism was
measured with a Seahorse XF24 Extracellular Flux Analyzer. Briefly, T cells were grown in high
glucose RPMI-1640 supplemented with 10% FCS. One hour before the experiment, 5 x 105 T
cells were seeded in a 24-well microplate in XF Assay Modified DMEM, and CXCL10, sodium
lactate, metabolic drugs, or PBS were injected during measurement. For glucose uptake and
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flux assays, 6-NBDG and 2-NBDG (Life), two fluorescent analogues of glucose that are taken
up by cells via glucose transporters, were used. Their fate differs upon cellular uptake. 6-NBDG
cannot be phosphorylated by hexokinase, the enzyme that initiates glycolysis, and accumulates
in the cytoplasm in its fluorescent form. 2-NBDG instead is phosphorylated by hexokinase and
transformed in nonfluorescent intermediates of the glycolytic pathway with kinetics dependent
on the pace of the glycolytic flux in the cell [49]. Therefore, parallel measurements of 6-NBDG
and 2-NBDG fluorescence provide a read out of glucose uptake and glycolytic flux in cells. T
cells were pre-treated with 2-DG, sodium-lactate or lactic-acid for 1 hour and then incubated
with the fluorescent probes 2-NBDG for 30 minutes or 6-NBDG for 10 minutes. At the end of
these treatments cells were harvested, washed twice with PBS and fluorescence read according
to the manufacturer’s instructions. T-cell viability upon lactate or metabolic drug treatment
was assessed by trypan blue exclusion assay.
CTL Differentiation and Activity Assay
Isolated CD8+ T cells (BALB/c) were incubated with CD3-depleted and mytomycin-C-eradi-
cated allogeneic splenocytes (C57BL/6). Differentiated CTLs were enriched with Ficoll and
CD3 enrichment kits and cocultured with endothelial cells (C57BL/6) in the presence or
absence of 10 mM lactic acid or sodium lactate. Dead cells were counted using trypan blue
exclusion assay 2, 4, 6, and 18 h after the start of the assay.
Th Subset Differentiation
T cells were isolated from murine lymph nodes and enriched for CD3+ and subsequently CD4+
subsets. 106 cells were plated/well and differentiated towards Th0, Th1, Th2, and Th17 pheno-
types. Conditions were: Th0 (10 ng/ml IL-2); Th1 (10 ng/ml IL-2; 3.4 ng/ml IL-12; 2 μg/ml
Anti-IL-4); Th2 (10 ng/ml IL-2; 10 ng/ml IL-4; 2 μg/ml Anti-IFN-γ); Th17 (10 ng/ml IL-6;
2 μg/ml Anti-IL-4; 2 μg/ml Anti-IFN-γ, 5 ng/ml TGF-β). All antibodies and cytokines were
purchased from PeproTech.
Intracellular Protein Staining
Murine T cells were incubated in permeabilization/fixation buffer (ebioscience) overnight at
4°C. Samples were washed in permeabilization buffer (ebioscience) and stained for the cyto-
kines IFN-γ and IL-17A, using fluorescently conjugated primary antibodies (1:200, ebios-
ciences) at 4°C for 30 min. Human-isolated CD4+ T cells were treated as described above. In
the final 4 h of culture, cells were treated with 50 ng/ml PMA and 500 ng/ml ionmycin and
1:1,000 Brefeldin A (Sigma-Aldrich), followed by surface staining for CD4 (clone RPA-T4, Bio-
legend). Cells were fixed and permeabilized as described above, followed by staining for IL-17A
(clone BL168, Biolegend) for 30 min at room temperature. All intracellular staining was
assessed by flow cytometry using a LSR Fortessa (BD Biosciences) and FlowJo version 7.6.5
software.
Human RA Synovial Tissue Collection and Immunohistology/
Immunofluorescence
RA synovial tissue was collected from a total of 16 RA patients undergoing total joint replace-
ment or ultrasound-guided synovial biopsies as previously described [50]. A summary of the
demographical and clinical characteristics of the RA patients is reported in S1 Table. For total
T cell scoring, paraffin sections were stained for CD3, and a semiquantitative score was applied
as previously described [35]. For Slc5a12 single and double (with CD4 or CD8)
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immunofluorescence, after antigen retrieval (S2367, Dako) and block of nonspecific binding,
slides were incubated with primary antibodies either overnight at 4°C (CD4 and CD8, 1:50,
Dako) or 1 h at RT (Slc5a12, 1:50, Novus Biologicals) followed by fluorochrome-conjugated
secondary antibodies (Invitrogen, Eugene, Oregon, USA). All sections were visualised using a
Zeiss fluorescence microscope. Quantification was performed by calculating the percent of
double positive CD4+ Slc5a12+ population within the CD4+ or Slc5a12+ cells and the percent
of double positive CD8+ Slc5a12+ population within the CD8+ or Slc5a12+ cells. The number
of positive cells (single and double positive for each marker) was counted in six images per
condition.
In Vivo Peritoneal Recruitment Model
Activated T cells (5 x 106/mouse) were pretreated overnight with Rapamycin (200 nM),
2-Deoxyglucose (1 mM), or Metformin (2 mM), then labelled with the fluorescent cell dye
DDAO (Invitrogen) and injected intravenously into syngeneic female C57BL/6 mice that had 3
h prior received an intraperitoneal injection of CXCL10 (1,200 ng/mouse). 24 h after injection,
mice were killed and spleen and peritoneal lavage were harvested. T cells were stained for sur-
face markers (CD4 and CD8, ebiosciences) and analysed by FACS. Cells were first gated on
CD4 and subsequently analysed for DDAO positivity. This method was used in Fig 3G and
S3E Fig.
In Vivo Zymosan-Induced Peritonitis
C57BL/6 mice were injected in the peritoneal cavity with zymosan (1 mg per mouse) on day 0
or left untreated. On day 5, Phloretin (50 μM), anti-Slc5a12 antibody (5 μg/ml) or anti-rabbit
IgG isotype control antibody (5 μg/ml; Invitrogen) were injected into the peritoneal cavity. 24
h later, mice were killed and the peritoneal lavage was harvested. T cells were stained for sur-
face markers (CD4 and CD8; ebiosciences) and analyzed by FACS. This method was used in
Fig 6B and S7A and S7B Fig. Alternatively C57BL/6 mice were injected in the peritoneal cavity
with zymosan (1 mg per mouse) on day 0. On day 5, activated CD4+ T cells (5 x 106/mouse)
labelled with the fluorescent cell dye CFSE (3.3μM; Invitrogen) were coinjected with anti-
Slc5a12 antibody (5 μg/ml), phloretin (50 μM), or an isotype control antibody (5 μg/ml) in the
peritoneal cavity. 24 h later, mice were killed and the peritoneal lavage and the spleen were har-
vested. T cells were stained for surface markers (CD4 and CD8; ebiosciences) and analyzed by
FACS. Cells were first gated on CD4 and subsequently analysed for CFSE positivity. This
method was used in Fig 6C and S7C Fig.
FACS
Isolated T cells were stained for surface markers; CD3, CD4, CD8, CD25, CXCR3, CCR7,
CD62L, and LFA-1 with fluorescently conjugated primary antibodies (1:200, ebiosciences) at
4°C for 30 min and assessed by flow cytometry using a LSR Fortessa (BD Biosciences) and
FlowJo version 7.6.5 software.
Statistical Analysis
Data are expressed as mean ± standard error of the mean (SEM). Two-tailed Student’s t test
was used to compare two groups with parametric data distribution. For multiple comparison
analysis, 1-, 2- or 3-way ANOVA was used. In all cases, a p-value of less than 5% was consid-
ered to be significant.
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Supporting Information
S1 Data. Excel spreadsheet containing, in separate sheets, the underlying numerical data
and statistical analysis for Figs 1A–1E, 2B–2D, 3A–3H, 4A–4D, 5B–5E, and 6A–6C.
(XLSX)
S2 Data. Excel spreadsheet containing, in separate sheets, the underlying numerical data
and statistical analysis for S1A–S1B, S2A–S2C, S3A–S3D, S3F, and S6 Figs.
(XLSX)
S1 Fig. Lactate inhibits T cell migration upon CCL5 stimulus and does not affect cellular
viability. (A) In vitro chemotaxis of activated CD4+ T cells towards CCL5 (50 ng/ml) in the
presence of lactic acid (10 mM) or sodium lactate (10 mM), shown as kinetic (left panel) and 4
h time point (right panel). (B) Total cell number of viable CD4+ T cells treated with CXCL10 in
the presence of lactic acid (10 mM) or sodium lactate (10 mM). (A left panel) Data is represen-
tative of three independent experiments; the underlying numerical data and statistical analysis
for each independent experiment can be found in the supporting file, S2 Data, S1A Fig (A right
panel, B) n = 3. (A–B) Underlying numerical data and statistical analysis can be found in the
supporting file, S2 Data, S1A–S1B Fig Values denote mean ± SD. p< 0.001.
(TIFF)
S2 Fig. Inhibition of T cell migration via blockade of lactate transporters is sub-type spe-
cific. (A) Western blots and qRT-PCR with Slc5a12-specific primers and RNAs from activated
CD4+ T cells expressing the shRNAs shown. (B, C) In vitro chemotaxis (4 h time point) of acti-
vated CD8+ T cells towards CXCL10 in the presence of lactic acid (10 mM) alone or in combi-
nation with an anti-Slc5a12 antibody (2.5 μg/ml) or an isotype control antibody (B left panel)
and two specific shRNAs for Slc5a12 or a nonspecific shRNA (B right panel), and activated
CD4+ T cells towards CXCL10 in the presence of sodium lactate alone or in combination with
CHC (425 μM) or phloretin (25 μM) (C left panel) and an anti-Slc16a1 (2.5 μg/ml) or an iso-
type control antibody, or AR-C155858 (8 nM) (C right panel). (A) Data is representative of
three independent experiments; the underlying numerical data and statistical analysis for each
independent experiment can be found in the supporting file, S2 Data, S2A Fig (B–C) n = 3. (A–
C) Underlying numerical data and statistical analysis can be found in the supporting file, S2
Data, S2A–S2C Fig Values denote mean ± SD.p< 0.05;  p< 0.01; p< 0.001.
(TIFF)
S3 Fig. Glycolysis and chemotaxis in naïve and activated CD4+ and CD8+ T cells. (A) West-
ern blots with antibodies against Hk1, aldolase A, PkM1/2, enolase 1, and β-actin in activated
CD8+ T cells treated with CXCL10 (1,000 ng/ml) or left untreated. Densitometric quantifica-
tion of western blots denotes mean ± SD, n = 3 (with biological replicates run in duplicate). (B)
Relative mRNA expression levels ofHk1, PkM2, and glucose transporters (Glut1, Glut2, Glut3,
and Glut4) in activated CD8+ T cells 6 h post-treatment with CXCL10 (1,000 ng/ml) as
assessed by qRT-PCR. mRNA levels in naive T cells were set to 1. (C) Measurements of glucose
uptake and flux in activated CD8+ T cells pretreated with 2-DG, sodium lactate or lactic acid
and then incubated with the fluorescent probes 6-NBDG or 2-NBDG. (D) ECAR trace of gly-
colytic activity expressed as mpH/min in activated CD4+ T cells treated with 2-DG (1 mM),
Rapamycin (200 nM), Metformin (2 mM) or Etomoxir (100 μM). (E) Representative FACS dot
plots of DDAO-labelled donor CD4+ T cells collected from the peritoneal lavage and spleen of
recipient mice, which correspond to the relative enrichment in peritoneal lavage shown in Fig
3G. (F) In vitro chemotaxis (4 h time point) towards the chemokines CCL19/21 (200 ng/ml of
each chemokine) of naïve T cells pretreated with Rapamycin (200 nM), 2-DG (1 mM) or
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Metformin (2 mM). (B, D) Data is representative of three (B) and two (D) independent experi-
ments; the underlying numerical data and statistical analysis for each independent experiment
can be found in the supporting file, S2 Data, S3B and S3D Fig (C, F) n = 3. (A–D, F) Underlying
numerical data and statistical analysis can be found in the supporting file, S2 Data, S3A–S3D
and S3F Fig Values denote mean ± SD. p< 0.05;  p< 0.01;  p<0.001.
(TIFF)
S4 Fig. Metabolic drugs do not affect CD4+/CD8+ T cell ratio and CD25 expression. Repre-
sentative FACS dot plots and histograms showing cell surface expression of CD4, CD8, and
CD25 on activated T cells treated with Rapamycin (200 nM), 2-DG (1 mM) or Metformin (2
mM) as assessed by flow cytometry.
(TIFF)
S5 Fig. Metabolic drugs do not affect T cell surface molecule phenotype and FSC/SSC pro-
file. Representative FACS dot plots and histograms showing FSC/SSC profile and cell surface
expression of CXCR3, CCR7, CD62L, and LFA-1 on activated T cells treated with Rapamycin
(200nM), 2-DG (1 mM) or Metformin (2 mM) as assessed by flow cytometry.
(TIFF)
S6 Fig. Cytokine expression profiles of Th0, Th1, Th2, and Th17 cell subsets. Relative
mRNA expression levels of the cytokines Ifn-γ, Tnf-β, Il-4, Il-5, Il-13, and Il-17 as assessed by
qRT-PCR. mRNA levels of each cytokine expressed by untreated Th0 cells were set to 1. Data is
representative of three independent experiments; the underlying numerical data and statistical
analysis for each independent experiment can be found in the supporting file, S2 Data, S6 Fig.
(TIFF)
S7 Fig. FACS dot plots of in vivo peritonitis model. (A, B) Representative peritoneal lavage
FACS dot plots of activated CD4+ (A) and CD8+ (B) T cells of C57BL/6 mice injected i.p. with
zymosan to induce peritonitis, and 5 d later treated with Slc5a12 specific antibody (5 μg/ml),
phloretin (50 μM) or isotype control antibody, which correspond to the CD4+ and CD8+ T
cells in the peritoneal lavage shown in Fig 6B. (C) Peritoneal lavage FACS dot plots of adop-
tively transferred CFSE-labeled activated CD4+ T cells, which are representative of the analyses
shown in Fig 6C.
(TIFF)
S1 Table. Demographical data of RA patients.
(DOCX)
S2 Table. List of primers used for qRT-PCR experiments.
(XLSX)
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